Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (651-660 of 962) with videos related to

Pageof 97
Sort By:
Lancet (London, England)|April 8, 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialSanjit S Jolly, Salim Yusuf, John Cairns, et al.
The American Journal of Cardiology|August 18, 2018
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)Mali D Worme, Mary K Tan, David W J Armstrong, et al.
Lancet (London, England)|August 17, 2010
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialEric J Topol, Marie-Germaine Bousser, Keith A A Fox, et al.
American Heart Journal|December 5, 2016
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT studyUsman Baber, George Dangas, David J Cohen, et al.
The Lancet. Neurology|March 17, 2023
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort studyPhilippa C Lavallée, Hugo Charles, Gregory W Albers, et al.
American Heart Journal|December 5, 2009
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registryTelly A Meadows, Deepak L Bhatt, Alan T Hirsch, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2019
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES TrialMichael Szarek, Ph Gabriel Steg, Dina DiCenso, et al.
Circulation. Cardiovascular Interventions|March 16, 2019
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical PresentationTullio Palmerini, Antonio G Bruno, Martine Gilard, et al.
Circulation|July 2, 2008
Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI)Nicolas Danchin, Pierre Coste, Jean Ferrières, et al.
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Pageof 97

Showing results (651-660 of 962) with videos related to

Sort By:
Pageof 97
Lancet (London, England)|April 8, 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialSanjit S Jolly, Salim Yusuf, John Cairns, et al.
The American Journal of Cardiology|August 18, 2018
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)Mali D Worme, Mary K Tan, David W J Armstrong, et al.
Lancet (London, England)|August 17, 2010
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialEric J Topol, Marie-Germaine Bousser, Keith A A Fox, et al.
American Heart Journal|December 5, 2016
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT studyUsman Baber, George Dangas, David J Cohen, et al.
The Lancet. Neurology|March 17, 2023
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort studyPhilippa C Lavallée, Hugo Charles, Gregory W Albers, et al.
American Heart Journal|December 5, 2009
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registryTelly A Meadows, Deepak L Bhatt, Alan T Hirsch, et al.
Circulation. Cardiovascular Quality and Outcomes|November 12, 2019
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES TrialMichael Szarek, Ph Gabriel Steg, Dina DiCenso, et al.
Circulation. Cardiovascular Interventions|March 16, 2019
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical PresentationTullio Palmerini, Antonio G Bruno, Martine Gilard, et al.
Circulation|July 2, 2008
Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI)Nicolas Danchin, Pierre Coste, Jean Ferrières, et al.
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Pageof 97